



Australian Government
Department of Health
Therapeutic Goods Administration

Therapeutic Goods Act 1989

**Approval under section 42DG for use of restricted representations by
Apotex Pty Ltd**

I, Nicole McLay, Delegate of the Secretary to the Department of Health, on receipt of an application on behalf of Apotex Pty Ltd, have approved under section 42DG(2) of the *Therapeutic Goods Act 1989* (the **Act**) the use of the below stated restricted representations in advertisements directed to consumers, for the following registered medicines:

APOHEALTH IRON TABLETS ferrous fumarate 200mg film coated tablets blister pack (AUST R 286619)

- a) *"Source of iron for the treatment and prevention of medically diagnosed iron deficiency and iron deficiency anaemias"; and/or*
- b) *"For use when iron deficiency anaemia has been diagnosed by your doctor and a therapeutic oral iron supplement is recommended as treatment or for ongoing prevention".*

APOHEALTH IRON TABLETS WITH FOLIC ACID ferrous fumarate 310mg and folic acid 0.35mg film coated tablets blister pack (AUST R 291162)

- a) *"Source of iron and folic acid for the prevention and treatment of medically diagnosed iron deficiency and folic acid deficiency anaemias"; and/or*
- b) *"For use when iron deficiency and folic acid deficiency anaemias have been diagnosed by your doctor and a therapeutic oral iron and folic acid supplement is recommended as treatment or for ongoing prevention"; and/or*
- c) *"For the treatment and prevention of medically diagnosed iron deficiency and folic acid deficiency anaemia".*

Dated this 19th day of October 2020

Signed electronically

Nicole McLay
Delegate of the Secretary to the Department of Health
Advertising Compliance Unit
Regulatory Practice, Education and Compliance Branch